Report of Foreign Issuer (6-k)
October 24 2018 - 6:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of:
October 2018 (Report No. 1)
Commission
file number:
001- 38041
THERAPIX
BIOSCIENCES LTD.
(Translation
of registrant’s name into English)
4
Ariel Sharon Street
HaShahar
Tower, 16th Floor
Givatayim
5320047, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
The
information contained in this Report (other than Exhibit 99.1) is hereby incorporated by reference into the Company’s Registration
Statement on Form F-3, File No. 333-225745 and Registration Statement on Form S-8, File No. 333-217765.
On
October 24, 2018, Therapix Biosciences Ltd. (the “Company”) issued a press release announcing the signing of a binding
letter of intent (the “LOI”) to be acquired (the “Transaction”) by FSD Pharma Inc. (“FSD”).
The all-stock Transaction values the Company at approximately $48 million (USD) and the shareholders of the Company will receive
FSD stock upon closing of the Transaction. The terms of the LOI will be superseded by a definitive agreement, which the parties
intend to execute within 30 days.
The
Transaction is subject to a number of customary conditions, including, but not limited to, the negotiation and execution of relevant
transaction documents, regulatory approvals, completion of satisfactory due diligence by FSD and the Company, and approval of
the Transaction by the shareholders of the Company. Subject to the satisfaction of these conditions and other conditions precedent,
the Transaction is anticipated to be completed by Q1 2019.
The
press release is attached as Exhibit 99.1 and is incorporated by reference herein.
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Therapix
Biosciences Ltd.
(Registrant)
|
|
|
|
|
By
|
/s/ Ascher
Shmulewitz
|
|
Name:
|
Ascher Shmulewitz, M.D, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Date:
October 24, 2018
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024